Neue Suche
Value in health
Verlag
ISSN
1098-3015
ZDBID
1471745-1
- HTA33 Analysis of the Implementation of Additive PICOs in a European Joint Health Technology Assessment – Implications of EU-HTA for Pharma
- HPR106 Gender-specific Drug Prices in Germany
- HTA161 German Early Benefit Assessments and the Impact of Medical Societies
- HTA157 Evidence Transfer in Europea) Drug Approval and (German) Early Benefit Assessments: An Empirical Analysis
- HTA 23 Application-Related Data Collection During Early Benefit Assessments in Germany: An Analysis of Current Procedures
- HTA238 Oncological Combination Therapies in the Context of the Early Benefit Assessment According to AMNOG
- MT45 Digital Health Applications in the General Practitioner Context of Care
- PMU39 Determinants of Willingness to Copay for Pharmaceuticals in Germany
- PNS175 Presentation of Drug DATA — a Significant Influence on the Assessment of Drugs?
- PCN15 DATA Transparency in Oncology — a Quantitative Analysis of Outcome Results in Amnog Documents and Clinicaltrials.Gov
- Pharmaceutical Pricing: Launch Strategy Rules?
- Patient-Focused Outcomes in the Among-Process – Status Quo and Quo Vadis
- Game Theory in the Healthcare Literature
- Open To The Public?
- Indirect Comparisons presented in German Benefit Assessments
- Time Restricted Decisions in German Benefit Assessments
- Epidemiological Data Presented in German Benefit Assessments
- HTA33 Analysis of the Implementation of Additive PICOs in a European Joint Health Technology Assessment – Implications of EU-HTA for Pharma
- HPR106 Gender-specific Drug Prices in Germany
- HTA161 German Early Benefit Assessments and the Impact of Medical Societies
- HTA157 Evidence Transfer in Europea) Drug Approval and (German) Early Benefit Assessments: An Empirical Analysis
- HTA 23 Application-Related Data Collection During Early Benefit Assessments in Germany: An Analysis of Current Procedures
- HTA238 Oncological Combination Therapies in the Context of the Early Benefit Assessment According to AMNOG
- MT45 Digital Health Applications in the General Practitioner Context of Care
- PMU39 Determinants of Willingness to Copay for Pharmaceuticals in Germany
- PNS175 Presentation of Drug DATA — a Significant Influence on the Assessment of Drugs?
- PCN15 DATA Transparency in Oncology — a Quantitative Analysis of Outcome Results in Amnog Documents and Clinicaltrials.Gov
- Pharmaceutical Pricing: Launch Strategy Rules?
- Patient-Focused Outcomes in the Among-Process – Status Quo and Quo Vadis
- Game Theory in the Healthcare Literature
- Open To The Public?
- Indirect Comparisons presented in German Benefit Assessments
- Time Restricted Decisions in German Benefit Assessments
- Epidemiological Data Presented in German Benefit Assessments